HomeMarket NewsStifel bullish on Lexeo Therapeutics, sees big potential in ataxia and Alzheimer's...

Stifel bullish on Lexeo Therapeutics, sees big potential in ataxia and Alzheimer’s treatment

Actionable Trade Ideas

always free

Large yellow signboard on metal frame with the word IPO


Stifel is singing the praises of Lexeo Therapeutics (NASDAQ:LXEO) by kicking off its coverage with a strong buy rating. The firm is particularly enthusiastic about Lexeo’s leading drug candidate, LX2006, for treating Friedreich’s ataxia and believes the potential of an Alzheimer’s therapy is being undervalued in the company’s stock.

The analysts at Stifel emphasized that Lexeo ticks all the right boxes – boasting promising early data, targeting commercially attractive indications with genuine unmet needs, flaunting an experienced management team, and having numerous upcoming catalysts that are set to propel the stock’s performance.

Looking at the bigger picture, Stifel foresees Lexeo reaping the benefits of a more adaptable regulatory landscape in cardiovascular gene therapy. Additionally, the analysts believe that despite the risks associated with it, Lexeo’s innovative Alzheimer’s therapy isn’t commanding the recognition it deserves in the current stock valuation.

Setting an optimistic tone, Stifel has pinned a price target of $20 for Lexeo’s stock, indicating strong confidence in the company’s future trajectory.

Swing Trading Ideas and Market Commentary

Need some new swing ideas? Get free weekly swing ideas and market commentary from Jonathan Bernstein here: Swing Trading.

Explore More

Weekly In-Depth Market Analysis and Actionable Trade Ideas

Get institutional-level analysis and trade ideas to take your trading to the next level, sign up for free and become apart of the community.